Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 591

2.

Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.

Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, Ballantyne CM, Ginsberg HN; COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators.

Clin Ther. 2007 Jul;29(7):1354-67.

PMID:
17825687
3.

Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia.

Mackness MI, Bhatnagar D, Durrington PN, Prais H, Haynes B, Morgan J, Borthwick L.

Eur J Clin Nutr. 1994 Dec;48(12):859-65.

PMID:
7889894
4.

Safety and efficacy of Omacor in severe hypertriglyceridemia.

Harris WS, Ginsberg HN, Arunakul N, Shachter NS, Windsor SL, Adams M, Berglund L, Osmundsen K.

J Cardiovasc Risk. 1997 Oct-Dec;4(5-6):385-91.

PMID:
9865671
5.

Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.

McKenney JM, Sica D.

Pharmacotherapy. 2007 May;27(5):715-28. Review.

PMID:
17461707
6.

Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group.

Mitropoulos KA, Armitage JM, Collins R, Meade TW, Reeves BE, Wallendszus KR, Wilson SS, Lawson A, Peto R.

Eur Heart J. 1997 Feb;18(2):235-41.

PMID:
9043839
7.

Effect of fish oil (n-3 polyunsaturated fatty acids) on plasma lipids, lipoproteins and inflammatory markers in HIV-infected patients treated with antiretroviral therapy: a randomized, double-blind, placebo-controlled study.

Thusgaard M, Christensen JH, Mørn B, Andersen TS, Vige R, Arildsen H, Schmidt EB, Nielsen H.

Scand J Infect Dis. 2009;41(10):760-6. doi: 10.1080/00365540903168056.

PMID:
19685375
8.

Long-term effects of fish oil on insulin resistance and plasma lipoproteins in NIDDM patients with hypertriglyceridemia.

Rivellese AA, Maffettone A, Iovine C, Di Marino L, Annuzzi G, Mancini M, Riccardi G.

Diabetes Care. 1996 Nov;19(11):1207-13.

PMID:
8908381
9.

Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia.

Rupp H.

Adv Ther. 2009 Jul;26(7):675-90. doi: 10.1007/s12325-009-0045-2. Epub 2009 Jul 27. Review.

PMID:
19629408
11.

The triglyceride-lowering effects of a modest dose of docosahexaenoic acid alone versus in combination with low dose eicosapentaenoic acid in patients with coronary artery disease and elevated triglycerides.

Schwellenbach LJ, Olson KL, McConnell KJ, Stolcpart RS, Nash JD, Merenich JA; Clinical Pharmacy Cardiac Risk Service Study Group.

J Am Coll Nutr. 2006 Dec;25(6):480-5.

PMID:
17229894
12.

Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia.

Wohl DA, Tien HC, Busby M, Cunningham C, Macintosh B, Napravnik S, Danan E, Donovan K, Hossenipour M, Simpson RJ Jr.

Clin Infect Dis. 2005 Nov 15;41(10):1498-504. Epub 2005 Oct 11.

PMID:
16231263
13.

Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.

Lewin AJ, Kipnes MS, Meneghini LF, Plotkin DJ, Perevozskaya IT, Shah S, Maccubbin DL, Mitchel YB, Tobert JA; Simvastatin/Thiazolidinedione Study Group.

Clin Ther. 2004 Mar;26(3):379-89.

PMID:
15110130
15.

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

Pyŏrälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G.

Diabetes Care. 1997 Apr;20(4):614-20. Erratum in: Diabetes Care 1997 Jun;20(6):1048.

PMID:
9096989
16.
17.

Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia.

Castaño G, Fernández L, Mas R, Illnait J, Gámez R, Mendoza S, Mesa M, Fernández J.

Drugs R D. 2005;6(4):207-19.

PMID:
16050054
18.

Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia.

Isaacsohn J, Hunninghake D, Schrott H, Dujovne CA, Knopp R, Weiss SR, Bays H, Crouse JR 3rd, Davidson MH, Keilson LM, McKenney J, Korenman SG, Dobs AS, Stein E, Krauss RM, Maccubbin D, Cho M, Plotkin DJ, Mitchel YB.

Clin Cardiol. 2003 Jan;26(1):18-24.

19.

[Efficacy and tolerability of simvastatin and omega-3 fatty acid combination in patients with coronary disease, hypercholesterolemia and hypertriglyceridemia].

Tomei R, Rossi L, Carbonieri E, Franceschini L, Cemin C, Ghebremariam-Tesfau K, Zardini P.

Cardiologia. 1993 Dec;38(12):773-8. Italian.

PMID:
8200011
20.

Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).

Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J.

Am J Cardiol. 2005 Feb 15;95(4):462-8. Erratum in: Am J Cardiol. 2006 Aug 1;98(3):427-8.

PMID:
15695129

Supplemental Content

Support Center